“`html

drug-Coated Balloons vs. Drug-Eluting stents: A 2025 Update on Coronary Revascularization

The landscape of percutaneous coronary intervention (PCI) is continually evolving, with advancements⁤ aimed at minimizing long-term complications and improving patient outcomes. A central debate revolves around the optimal ‍approach to treating coronary artery disease: should we favor drug-coated balloons (DCBs) or traditional drug-eluting stents (DES)? This article provides a ⁤thorough overview of the current evidence, focusing on recent trials like the REC-CAGEFREE I study, and offers insights into the practical implications‍ for cardiologists and patients in 2025. We’ll delve into the nuances of each technology, explore the latest data on safety and efficacy, and discuss the future direction of coronary revascularization ⁤strategies. Understanding these differences is crucial, especially given the projected 1.1% ⁤annual growth rate of the global PCI devices market, reaching an estimated $11.8 billion by 2028 (Global Market ⁣Insights, 2024).

Understanding⁢ the Technologies: DCBs and DES

Both dcbs and DES are utilized during PCI to restore blood flow in narrowed or blocked coronary arteries. ⁢However, they differ considerably in their mechanism of action. DES, the established standard for many years, involve the implantation of a metallic scaffold⁣ coated with a drug that inhibits cell proliferation, preventing restenosis – the re-narrowing of the artery. DCBs, conversely, deliver medication directly to the vessel wall without ⁤leaving a permanent implant. This approach aims to reduce the risk of late stent thrombosis and the need for prolonged dual antiplatelet therapy (DAPT). The appeal of DCBs lies in their potential to offer a more⁢ ‘natural’ approach‍ to⁣ vessel⁤ healing, avoiding the long-term presence of a foreign body.

The REC-CAGEFREE I Trial: A‍ Closer Look

Recent research, notably the REC-CAGEFREE I trial conducted by Gao and colleagues, has provided valuable data regarding the comparative effectiveness of DCBs and DES. Published in late 2025, this open-label, randomized, non-inferiority trial assessed patients presenting ⁣with de novo,⁢ non-complex⁤ coronary lesions. ‍The study compared ⁤a DCB-only strategy against a ‍DES implantation approach.While the⁤ DCB group did not demonstrate non-inferiority to DES in terms of primary endpoints, the overall event rates at two years were remarkably low in both arms. This suggests that both strategies are viable options for appropriately selected patients.

The REC-CAGEFREE I trial demonstrated the safety of DCB-only angioplasty,with exceptionally low rates of acute occlusions (0% in the DCB group versus 1% in the DES group) and vessel thrombosis (0.4% vs 0.3%).

Gao et al., ⁢2025

Importantly, the trial highlighted the exceptional safety⁣ profile of DCB-only angioplasty. The incidence of acute occlusions and vessel thrombosis was exceedingly low in both groups, indicating ‍that